Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vinflunine+ ketaconazole · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vinflunine + ixabepilone | DRUG | solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration |
| vinflunine + ketaconazole | DRUG | vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration |
Inclusion Criteria: * ECOG status of 0-1 Exclusion Criteria: * Inability to tolerate venous access * Brain mets * Severe nerve damage * ANC \<2,000/mm3 * Platelets \<100K * Bilirubin \>= 1.5 times the IULN * ALT/AST \>= 2.5 times the IULN * Creatinine \<50 mL/min * Prior treatment with vinflunine...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Vinflunine is an investigational small molecule being studied for the treatment of several cancers, including breast cancer, bladder cancer, prostate cancer, small cell carcinoma, and transitional cell carcinoma. It is in Phase 2 clinical development and has not been approved by the FDA.
Vinflunine is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various oncology indications.
Vinflunine is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. All completed trials for Vinflunine are Phase 2 studies, and there are no active trials currently ongoing.
Vinflunine has been studied in several Phase 2 clinical trials, including NCT00101608 for transitional cell carcinoma of the urothelium, NCT00284154 for relapsed extensive small cell lung cancer, NCT00284180 for HER2-overexpressing metastatic breast cancer, and NCT00389155 for advanced bladder cancer.
Vinflunine is a small molecule that works by targeting microtubules, which are essential for cell division. By interfering with microtubule dynamics, it disrupts cancer cell proliferation. This mechanism is typical of vinca alkaloid class drugs used in oncology.